Core Viewpoint - The company is forecasting a significant decline in net profit for 2025, alongside changes in its auditing team and the acquisition of laboratory accreditation. Group 1: Financial Performance - The company expects its net profit attributable to shareholders for 2025 to be between 44 million to 56 million yuan, representing a year-on-year decrease of 67.37% to 74.36% due to factors such as goodwill impairment, declining gross margin, and exchange rate fluctuations [2] - The final data will be confirmed in the official annual report, which has not yet been released [2] Group 2: Company Status - The company announced a change in its signing auditor for the 2025 fiscal year due to internal adjustments within the firm, with Yang Guoqing appointed as the new signing auditor, who possesses the necessary professional qualifications [3] - This change is not expected to affect the auditing process [3] Group 3: Business Development - The company received the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS), valid until 2032, which will enhance its testing capabilities and international recognition [4]

Core Viewpoint - Gongdong Medical (605369) has shown a price increase of 3.17% this week, closing at 19.51 yuan, with a total market capitalization of 4.302 billion yuan [1] Company Announcements - Gongdong Medical's testing center has received accreditation from the China National Accreditation Service for Conformity Assessment (CNAS), with a registration number CNAS L25064, valid until January 18, 2032 [1] - The accreditation indicates that the testing center meets the ISO/IEC 17025:2017 standards, enhancing its testing capabilities and gaining national and international recognition [1] - This recognition will help reduce market entry barriers and testing costs for products, improve quality control and R&D capabilities, and increase customer trust, although it is not expected to have a significant impact on the company's operating performance [1]

Group 1 - The core point of the article is that Gongdong Medical (605369) has received the CNAS laboratory accreditation, which enhances its testing capabilities and international recognition, although it will not significantly impact the company's financial performance [1][2] - On February 3, 2026, Gongdong Medical's stock closed at 19.26 yuan, down 1.03%, with a turnover rate of 1.58% and a trading volume of 34,800 shares, amounting to a transaction value of 67.5 million yuan [1] - The net outflow of main funds on February 3 was 604.08 million yuan, accounting for 8.95% of the total transaction value, while retail investors experienced a net outflow of 224.98 million yuan, representing 3.33% of the total transaction value [1][2] Group 2 - The CNAS accreditation certificate obtained by Gongdong Medical's testing center is valid until January 18, 2032, and confirms compliance with ISO/IEC 17025:2017 standards [1] - The international mutual recognition of testing results will help reduce market entry barriers and testing costs for products, thereby improving quality control and R&D innovation capabilities [1]

Core Viewpoint - Gongdong Medical (605369.SH) has announced that its testing center meets the requirements of ISO/IEC 17025:2017 and has obtained the CNAS laboratory accreditation certificate, indicating a significant enhancement in its management and technical capabilities [1] Group 1 - The acquisition of the CNAS laboratory accreditation certificate signifies national and international recognition of the company's testing center's management level and technical ability [1] - This certification will help reduce the market entry barriers and external testing costs for the company's products in both domestic and international markets [1] - The recognition supports product quality control, performance validation, and research and development innovation, thereby enhancing the company's overall competitiveness [1]

Market Overview - The medical device sector experienced a decline of 1.98% on February 2, with Hai Li Biological leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Top Performers - Mai Pu Medical (301033) saw a closing price of 73.70, with an increase of 8.35% and a trading volume of 31,100 shares, totaling 223 million yuan [1] - Nanwei Co., Ltd. (603880) closed at 6.63, up 5.41%, with a trading volume of 191,200 shares, amounting to 126 million yuan [1] - Gongdong Medical (605369) closed at 19.46, up 2.91%, with a trading volume of 44,800 shares, totaling 86.97 million yuan [1] Underperformers - Hai Li Biological (603718) closed at 5.84, down 10.02%, with a trading volume of 84,500 shares, totaling 49.32 million yuan [2] - Yuanmei Medical (002950) closed at 10.46, down 9.52%, with a trading volume of 255,000 shares, amounting to 269 million yuan [2] - Yikang Technology (688301) closed at 111.34, down 5.92%, with a trading volume of 44,200 shares, totaling 503 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 533 million yuan from institutional investors, while retail investors experienced a net inflow of 174 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Individual Stock Capital Flow - Sino Medical (688108) had a net inflow of 46.28 million yuan from institutional investors, while retail investors saw a net outflow of 58.30 million yuan [3] - Mai Pu Medical (301033) experienced a net inflow of 29.68 million yuan from institutional investors, with a net outflow of 34.84 million yuan from retail investors [3] - Gongdong Medical (605369) had a net inflow of 13.18 million yuan from institutional investors, while retail investors faced a net outflow of 9.00 million yuan [3]

Core Viewpoint - Gongdong Medical (605369.SH) has received the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS), indicating the company's laboratory management and technical capabilities have gained national and international recognition [1] Group 1: Accreditation Impact - The CNAS accreditation signifies that the company's testing center can conduct tests according to national standards, with results recognized internationally [1] - This accreditation helps reduce the market entry barriers and external testing costs for products in both domestic and international markets [1] - It provides a solid guarantee for product quality control, performance validation, and research innovation, enhancing customer recognition and trust in the company [1] Group 2: Competitive Advantage - The achievement highlights the company's advantages in technical and quality management standards [1] - It is expected to improve the company's overall competitiveness in the industry [1]

Core Viewpoint - Gongdong Medical (605369.SH) has received the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS), indicating its management and technical capabilities have gained national and international recognition [1] Group 1: Accreditation Impact - The CNAS accreditation signifies that the company's testing center can conduct tests according to national standards, with results recognized internationally [1] - This accreditation helps reduce the market entry barriers and external testing costs for products in both domestic and international markets [1] Group 2: Quality and Trust Enhancement - The recognition enhances the company's ability to ensure product quality control, performance validation, and research innovation [1] - It also increases customer recognition and trust in the company, showcasing its advantages in technical and quality management [1] Group 3: Competitive Advantage - The accreditation is expected to improve the company's overall competitiveness in the industry [1]

浙江拱东医疗器械股份有限公司（以下简称"公司"）于近日收到中国合格 评定国家认可委员会（以下简称"CNAS"）授予的实验室认可证书，现将具体 情况公告如下： 一、基本情况 获证机构名称：浙江拱东医疗器械股份有限公司检验中心 注册号：CNAS L25064 生效日期：2026-01-19 证券代码：605369 证券简称：拱东医疗 公告编号：2026-003 浙江拱东医疗器械股份有限公司 关于获得中国合格评定国家认可委员会（CNAS） 实验室认可证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 CNAS 是根据《中华人民共和国认证认可条例》《认可机构监督管理办法》 的规定，依法经国家市场监督管理总局确定，从事认证机构、实验室、检验机构、 审定与核查机构等合格评定机构认可评价活动的权威机构，负责合格评定机构国 家认可体系运行。 中国合格评定国家认可制度在国际认可活动中有着重要的地位，其认可活动 已融入国际认可互认体系，并发挥着重要的作用。CNAS 是国际实验室认可合作 组织（ILAC）和亚太认可合作组织（APAC）的互认 ...

Core Viewpoint - The company has received a laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS), which enhances its management and technical capabilities, providing international recognition of its testing results [1] Group 1 - The accredited institution is the company's testing center, with the certificate registration number CNASL25064 [1] - The certificate is effective from January 19, 2026, to January 18, 2032 [1] - This accreditation will help reduce costs and improve competitiveness, although it is not expected to have a significant impact on the company's operating performance [1]

Core Viewpoint - As of January 30, 2026, Gongdong Medical (605369) closed at 18.91 yuan, down 3.77% from the previous week's 19.65 yuan, indicating a decline in stock performance [1] Company Performance - The highest intraday price for Gongdong Medical on January 26 was 19.94 yuan, while the lowest intraday price on January 29 was 18.71 yuan [1] - The current total market capitalization of Gongdong Medical is 4.17 billion yuan, ranking 91 out of 127 in the medical device sector and 3975 out of 5184 in the A-share market [1] Company Announcements - Gongdong Medical announced a change in the signing accountant for the 2025 fiscal year, with Yang Guoqing added as a signing registered accountant [1] - The previous signing accountants were Ning Yifeng and Guo Senhao from Tianjian Accounting Firm, but due to internal adjustments, the change was made [1] - Yang Guoqing has been a certified public accountant since 2015 and has signed or reviewed audit reports for listed companies such as Wansheng Intelligent and Great Wall Technology in the past three years, demonstrating relevant professional capability and independence [1] - The change in accountants is not expected to adversely affect the company's financial statements or internal control audit for the 2025 fiscal year [1]